Compare Altria Group Inc (MO) vs Merck & Co., Inc. (MRK) Price & Performance

Altria Group IncTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Altria Group Inc vs Merck & Co., Inc. — how do they compare? Altria Group Inc trades at $74.53 (market cap $124.67B), while Merck & Co., Inc. trades at $126.01 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 2.5× Altria Group Inc's market cap, and Altria Group Inc pays the higher dividend (5.68%). Which is the better fit depends on your goals.

	MO	MRK
Market Cap	$124.67B	$307.25B
Sector	Consumer Staples	Health
52-Week High	$74.66	$129.52
52-Week Low	$54.72	$77.60
Enterprise Value	$145.75B	$350.66B
Dividend Yield	5.68%	2.73%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Altria Group Inc

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.

The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

Dividend Harvesting Portfolio tops $40K with 43.6% return, focusing on growing income and tech sector bets.Seeking Alpha · 1 day agoBullish SPYI ETF yields 12% but faces pressure as volatility drops and Treasury yields rise.24/7 Wall Street · 4 days agoNeutral View details →

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 3 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 1 day agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

About Altria Group Inc

Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.